Skip to main content

Direct to Tumor: Transarterial Administration of Gold Nanoshells with Enhanced Targeting and Photothermal Therapy

Buy Article:

$107.14 + tax (Refund Policy)

Inspired by transcatheter arterial chemoembolization, a novel tumor therapy strategy was developed based on the transarterial embolization technique and selective photothermal ablation using gold nanoshells on silica nanorattles (GSNs). With the use of transarterial administration, GSNs directly entered the arteries feeding the tumor, avoiding circulation throughout the body and elimination by the reticuloendothelial system (RES). As a result, enhanced retention and permeability of GSNs in tumor tissue was observed by Inductively Coupled Plasma-Optical Emission Spectrometer (ICP-OES), which showed that the Au content was 3–6 times higher in tumors when delivered by arterial injection than by intravenous injection. Utilizing the near-infrared (NIR) plasmonic absorbance of those nanoparticles, selective photothermal tumor ablation was achieved and an excellent antitumor effect was monitored by CT imaging for post-treatment prognosis. Additionally, a comparative study on the in vivo biodistribution and safety was performed and benign biocompatibility was elucidated. The transarterial administration of GSNs directly into tumors makes it possible to advance the clinical application of photothermal nanomaterials.

Keywords: GOLD NANOSHELLS; LIVER TUMOR; PHOTOTHERMAL THERAPY; SILICA NANORATTLES; TRANSARTERIAL ADMINISTRATION

Document Type: Research Article

Publication date: 01 July 2017

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content